NVS NYSE
Novartis AG
1W: +2.4%
1M: +5.7%
3M: -3.8%
YTD: +11.0%
1Y: +16.8%
3Y: +72.8%
5Y: +121.5%
$156.86
+3.05 (+1.98%)
After Hours: $156.15 (-0.71, -0.45%)
Weekly Expected Move ±3.4%
$141
$146
$151
$156
$162
Credit Risk of going bust: lower than 80% of companies Debt: 14.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.81 (down 99%), Novartis AG would be worth roughly what it owes.
Total debt $49.01B against a stock market value of $292.35B.
Distance to default 9.62 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $28.61B (short-term plus half of long-term), stock volatility 27.6%; Altman Z'' 2.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $49.01B against a stock market value of $292.35B.
Distance to default 9.62 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $28.61B (short-term plus half of long-term), stock volatility 27.6%; Altman Z'' 2.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$292.3B
52W Range121.57-170.46
Volume2,815,397
Avg Volume2,027,542
Beta0.42
Dividend$4.74
Analyst Ratings
Company Info
CEOVasant Narasimhan
Employees75,267
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date1996-11-07
Websitenovartis.com
Lichtstrasse 35
Basel, BS 4056
CH
Basel, BS 4056
CH
41 61 324 1111
About Novartis AG
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Latest News
Novartis (NVS) Q3 2026 Earnings Call Transcript
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP
Recent Insider Trades
No insider trades found